Bionovo
Bionovo, Inc. was a pharmaceutical company focused on the discovery and development of drugs derived from botanical sources. The company was headquartered in Emeryville, California, and was publicly traded on the NASDAQ stock exchange under the ticker symbol BNVI.
History[edit]
Bionovo was founded in 2002 by Dr. Isaac Cohen and Dr. Mary Tagliaferri. The company aimed to develop novel treatments for cancer and women's health, leveraging traditional Chinese medicine and modern scientific techniques.
Research and Development[edit]
Bionovo's research primarily focused on two main areas: oncology and women's health. The company's lead product candidates included:
- Menerba - A drug candidate for the treatment of menopausal symptoms.
- Bezielle - An investigational drug for the treatment of breast cancer.
Menerba[edit]
Menerba was designed to treat menopausal symptoms such as hot flashes and night sweats. It was a selective estrogen receptor beta agonist, which aimed to provide the benefits of estrogen without the associated risks of hormone replacement therapy.
Bezielle[edit]
Bezielle was developed for the treatment of advanced breast cancer. It was derived from a botanical source and aimed to induce cancer cell death without harming normal cells.
Clinical Trials[edit]
Bionovo conducted several clinical trials to evaluate the safety and efficacy of its drug candidates. The company faced challenges in advancing its products through the clinical trial phases, which ultimately impacted its financial stability.
Financial Challenges and Closure[edit]
Despite initial promise, Bionovo struggled with financial difficulties. The company faced challenges in securing sufficient funding to continue its research and development activities. In 2012, Bionovo announced that it was suspending its clinical trials due to a lack of funds. The company eventually ceased operations and filed for bankruptcy.
Legacy[edit]
Bionovo's work contributed to the understanding of botanical sources in drug development, particularly in the areas of oncology and women's health. Although the company did not succeed in bringing its products to market, its research efforts provided valuable insights for future studies.
Related Pages[edit]
Categories[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends ✔ Tele visits available with certain limitations Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
